Shandong Realcan Pharmaceutical Co Ltd Net Asset Quality Index
Shandong Realcan Pharmaceutical Co Ltd net asset quality index. Shandong Realcan Pharmaceutical Co Ltd (002589) has a Net Asset Quality Index of 35.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥15.55 Billion minus total liabilities of CN¥10.10 Billion yields net assets of CN¥5.44 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check earnings quality score of Shandong Realcan Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
Net asset quality index of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025. This chart shows how Shandong Realcan Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the index stands at 35.0%, representing net assets of CN¥5.44 Billion against total assets of CN¥15.55 Billion CNY. See Shandong Realcan Pharmaceutical Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Shandong Realcan Pharmaceutical Co Ltd Net Asset Quality Index by Year (2008–2025)
Shandong Realcan Pharmaceutical Co Ltd net asset quality index by year from 2008 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 002589 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 37.7% | CN¥5.42 Billion | CN¥14.37 Billion | CN¥8.95 Billion | ▲ +2.2 pp |
| 2024 | 35.6% | CN¥5.69 Billion | CN¥16.01 Billion | CN¥10.32 Billion | ▲ +1.8 pp |
| 2023 | 33.7% | CN¥5.64 Billion | CN¥16.71 Billion | CN¥11.07 Billion | ▲ +2.4 pp |
| 2022 | 31.4% | CN¥5.75 Billion | CN¥18.33 Billion | CN¥12.58 Billion | ▼ -5.3 pp |
| 2021 | 36.7% | CN¥9.69 Billion | CN¥26.40 Billion | CN¥16.70 Billion | ▲ +5.9 pp |
| 2020 | 30.8% | CN¥9.64 Billion | CN¥31.29 Billion | CN¥21.65 Billion | ▼ -0.8 pp |
| 2019 | 31.6% | CN¥10.25 Billion | CN¥32.47 Billion | CN¥22.21 Billion | ▼ -0.9 pp |
| 2018 | 32.5% | CN¥11.31 Billion | CN¥34.84 Billion | CN¥23.53 Billion | ▼ -3.4 pp |
| 2017 | 35.9% | CN¥9.67 Billion | CN¥26.98 Billion | CN¥17.31 Billion | ▼ -12.1 pp |
| 2016 | 47.9% | CN¥7.50 Billion | CN¥15.66 Billion | CN¥8.15 Billion | ▲ +9.5 pp |
| 2015 | 38.4% | CN¥3.40 Billion | CN¥8.86 Billion | CN¥5.46 Billion | ▲ +6.3 pp |
| 2014 | 32.1% | CN¥1.83 Billion | CN¥5.68 Billion | CN¥3.85 Billion | ▼ -4.9 pp |
| 2013 | 37.0% | CN¥1.65 Billion | CN¥4.45 Billion | CN¥2.80 Billion | ▲ +7.7 pp |
| 2012 | 29.4% | CN¥916.39 Million | CN¥3.12 Billion | CN¥2.20 Billion | ▼ -7.5 pp |
| 2011 | 36.8% | CN¥817.11 Million | CN¥2.22 Billion | CN¥1.40 Billion | ▲ +16.8 pp |
| 2010 | 20.0% | CN¥296.03 Million | CN¥1.48 Billion | CN¥1.18 Billion | ▼ -2.5 pp |
| 2009 | 22.5% | CN¥234.18 Million | CN¥1.04 Billion | CN¥805.78 Million | ▲ +6.9 pp |
| 2008 | 15.6% | CN¥111.89 Million | CN¥715.53 Million | CN¥603.64 Million | — |